TABLE II.

Comparison of blocker impact on RIV for all HBE monolayers

Drug orderBasalForskolinGlyH-101Forskolin+GlyH-101Forskolin+GlibenclamideGlyH-101+ForskolinGlibenclamide+Forskolin
wtHBE1.06 ± 0.011.06 ± 0.020.97 ± 0.010.83 ± 0.031.39 ± 0.140.89 ± 0.011.50 ± 0.03
GP adjusteda1.17 ± 0.060.90 ± 0.050.66 ± 0.03
  • Order of agonist or blocker represents experimental additions. Each measurement represents an n ≥ 6.

  • a Values calculated with correction for paracellular conductance.